These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 19841860)

  • 1. Serum homocysteine, folate and vitamin B12 in patients with Paget's disease of bone: the effect of zoledronic acid.
    Polyzos SA; Anastasilakis AD; Efstathiadou Z; Litsas I; Kita M; Panagiotou A; Papatheodorou A; Arsos G; Moralidis E; Barmpalios G; Zafeiriadou E; Triantafillidou E; Makrigiannaki E; Terpos E
    J Bone Miner Metab; 2010 May; 28(3):314-9. PubMed ID: 19841860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between bone mineral density, bone turnover markers and homocysteine, folate and vitamin B12 levels in postmenopausal women.
    Haliloglu B; Aksungar FB; Ilter E; Peker H; Akin FT; Mutlu N; Ozekici U
    Arch Gynecol Obstet; 2010 Apr; 281(4):663-8. PubMed ID: 19946695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.
    Xu XJ; Ma DD; Lv F; Wang JY; Liu Y; Xia WB; Jiang Y; Wang O; Xing XP; Yu W; Li M
    Endocr Pract; 2016 Nov; 22(11):1267-1276. PubMed ID: 27482615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin, and RANKL in patients with Paget's disease of bone.
    Polyzos SA; Anastasilakis AD; Efstathiadou Z; Kita M; Litsas I; Avramidis A; Arsos G; Moralidis E; Gerou S; Pavlidou V; Papatheodorou A; Terpos E
    Horm Metab Res; 2009 Nov; 41(11):846-50. PubMed ID: 19670154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-energy X-ray absorptiometry and quantitative ultrasound in patients with Paget's disease of bone before and after treatment with zoledronic acid: association with serum bone markers and Dickkopf-1.
    Polyzos SA; Anastasilakis AD; Litsas I; Sapranidis M; Efstathiadou Z; Kita M; Arsos G; Moralidis E; Zafeiriadou E; Papatheodorou A; Terpos E
    J Clin Densitom; 2010; 13(2):190-6. PubMed ID: 20347367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours.
    Santini D; Vincenzi B; Hannon RA; Brown JE; Dicuonzo G; Angeletti S; La Cesa A; Coleman RE; Tonini G; Budillon A; Caraglia M; Holen I
    Oncol Rep; 2006 May; 15(5):1351-7. PubMed ID: 16596210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
    Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
    Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Folate supplementation does not affect biochemical markers of bone turnover.
    Herrmann M; Stanger O; Paulweber B; Hufnagl C; Herrmann W
    Clin Lab; 2006; 52(3-4):131-6. PubMed ID: 16584059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.
    Hirsh V; Major PP; Lipton A; Cook RJ; Langer CJ; Smith MR; Brown JE; Coleman RE
    J Thorac Oncol; 2008 Mar; 3(3):228-36. PubMed ID: 18317064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folate, vitamin B12 and Homocysteine status in the post-folic acid fortification era in different subgroups of the Brazilian population attended to at a public health care center.
    Barnabé A; Aléssio AC; Bittar LF; de Moraes Mazetto B; Bicudo AM; de Paula EV; Höehr NF; Annichino-Bizzacchi JM
    Nutr J; 2015 Feb; 14():19. PubMed ID: 25886278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.
    Anastasilakis AD; Polyzos SA; Gkiomisi A; Bisbinas I; Gerou S; Makras P
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer.
    Francini F; Pascucci A; Bargagli G; Francini E; Conca R; Miano ST; Martellucci I; Migali C; Gotti G; Fiaschi AI; Cozzolino A; Petrioli R
    Int J Clin Oncol; 2011 Jun; 16(3):264-9. PubMed ID: 21240683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum homocysteine, folate, vitamin B12 levels and arterial stiffness in diabetic patients: which of them is really important in atherogenesis?
    Shargorodsky M; Boaz M; Pasternak S; Hanah R; Matas Z; Fux A; Beigel Y; Mashavi M
    Diabetes Metab Res Rev; 2009 Jan; 25(1):70-5. PubMed ID: 19065546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.
    Alcaraz A; González-López R; Morote J; de la Piedra C; Meseguer C; Esteban E; Climent M; González-Gragera B; Alvarez-Ossorio JL; Chirivella I; Mellado B; Lara PC; Vázquez F; Contreras JA; Carles J; Murias A; Calderero V; Comet-Batlle J; González-Del Alba A; León-Mateos L; Mañas A; Segarra J; Lassa A; González-Enguita C; Méndez MJ; Samper P; Unda M; Mahillo-Fernández I; Bellmunt J;
    Br J Cancer; 2013 Jul; 109(1):121-30. PubMed ID: 23799855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additive effects of zoledronic acid and propranolol on bone density and biochemical markers of bone turnover in osteopenic ovariectomized rats.
    Khajuria DK; Razdan R; Mahapatra DR
    Rev Bras Reumatol; 2015; 55(2):103-12. PubMed ID: 25582996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of Homocysteine, Vitamin B12 and Folate in Patients with Multiple Sclerosis: an Updated Meta-Analysis.
    Li X; Yuan J; Han J; Hu W
    Int J Med Sci; 2020; 17(6):751-761. PubMed ID: 32218697
    [No Abstract]   [Full Text] [Related]  

  • 18. Plasma Homocysteine and Serum Folate and Vitamin B
    Ma F; Wu T; Zhao J; Ji L; Song A; Zhang M; Huang G
    Nutrients; 2017 Jul; 9(7):. PubMed ID: 28698453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis.
    Catalano A; Morabito N; Basile G; Brancatelli S; Cucinotta D; Lasco A
    J Clin Endocrinol Metab; 2013 May; 98(5):1911-5. PubMed ID: 23596142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
    Liang BC; Shi ZY; Wang B; Wu P; Kong LC; Yao JL; Li CW; Shi XL
    Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.